Tapio Visakorpi

List of Publications by Year in Descending Order

125 papers	12,135 citations	49 h-index	110 g-index
144 ext. papers	13,566 ext. citations	9 avg, IF	5.9 L-index

#	Paper	IF	Citations
125	Spatial analysis of histology in 3D: quantification and visualization of organ and tumor level tissue environment.. *Heliyon*, **2022**, 8, e08762	3.6	1
124	miR-32 promotes MYC-driven prostate cancer.. *Oncogenesis*, **2022**, 11, 11	6.6	0
123	Expression and ERG regulation of PIM kinases in prostate cancer. *Cancer Medicine*, **2021**, 10, 3427-3436	4.8	5
122	Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells. *Oncogene*, **2021**, 40, 4567-4579	9.2	8
121	Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. *Nature Communications*, **2021**, 12, 5307	17.4	9
120	AR and ERG drive the expression of prostate cancer specific long noncoding RNAs. *Oncogene*, **2020**, 39, 5241-5251	9.2	2
119	Integrative proteomics of prostate cancer. *Current Opinion in Endocrine and Metabolic Research*, **2020**, 10, 43-49	1.7	
118	Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts. *BMC Research Notes*, **2020**, 13, 311	2.3	8
117	Reply by Authors. *Journal of Urology*, **2020**, 204, 77-78	2.5	
116	Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate. *Journal of Urology*, **2020**, 204, 71-78	2.5	4
115	Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy. *Nature Communications*, **2020**, 11, 5070	17.4	18
114	Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors. *Histology and Histopathology*, **2020**, 35, 673-680	1.4	
113	Phosphorylation of NFATC1 at PIM1 target sites is essential for its ability to promote prostate cancer cell migration and invasion. *Cell Communication and Signaling*, **2019**, 17, 148	7.5	7
112	A Four-kallikrein Panel and Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. *European Urology Focus*, **2019**, 5, 561-567	5.1	7
111	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. *Nature Genetics*, **2018**, 50, 682-692	36.3	112
110	Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer. *Pathology Research and Practice*, **2018**, 214, 848-856	3.4	8
109	Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. *Nature Communications*, **2018**, 9, 1176	17.4	84

108	Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies. *Translational Oncology*, **2018**, 11, 1160-1170	4.9	14
107	Comparative analysis of tissue reconstruction algorithms for 3D histology. *Bioinformatics*, **2018**, 34, 3013-3021	7.3	13
106	Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. *British Journal of Cancer*, **2018**, 119, 347-356	8.7	38
105	Differential impact of RB status on E2F1 reprogramming in human cancer. *Journal of Clinical Investigation*, **2018**, 128, 341-358	15.9	58
104	Proteomics of prostate cancer - revealing how cancer cells master their messy genomes. *Oncoscience*, **2018**, 5, 216-217	0.8	3
103	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. *Cell Reports*, **2017**, 19, 2045-2059	10.6	72
102	Analysis of spatial heterogeneity in normal epithelium and preneoplastic alterations in mouse prostate tumor models. *Scientific Reports*, **2017**, 7, 44831	4.9	5
101	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. *PLoS Genetics*, **2017**, 13, e1007001	6	20
100	In Vivo Expression of miR-32 Induces Proliferation in Prostate Epithelium. *American Journal of Pathology*, **2017**, 187, 2546-2557	5.8	10
99	The expression of AURKA is androgen regulated in castration-resistant prostate cancer. *Scientific Reports*, **2017**, 7, 17978	4.9	23
98	Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. *Neuro-Oncology*, **2017**, 19, 1206-1216	11	12
97	Tumor features and survival after radical prostatectomy among antidiabetic drug users. *Prostate Cancer and Prostatic Diseases*, **2016**, 19, 367-373	6.2	11
96	Benchmarking of algorithms for 3D tissue reconstruction **2016**,		1
95	Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status. *Human Molecular Genetics*, **2016**, 25, 5490-5499	5.6	6
94	Measuring the Expression of microRNAs Regulated by Androgens. *Methods in Molecular Biology*, **2016**, 1443, 151-63	1.4	
93	Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene. *Genes Chromosomes and Cancer*, **2016**, 55, 661-73	5	4
92	The Potential of MicroRNAs as Prostate Cancer Biomarkers. *European Urology*, **2016**, 70, 312-22	10.2	169
91	Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. *Molecular Oncology*, **2016**, 10, 825-37	7.9	18

90	Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers. *Oncotarget*, **2016**, 7, 51965-51980	3.3	28
89	Incidence of Mucinous Metaplasia in the Prostate of FVB/N Mice (Mus musculus). *Comparative Medicine*, **2016**, 66, 286-9	1.6	2
88	A comprehensive repertoire of tRNA-derived fragments in prostate cancer. *Oncotarget*, **2016**, 7, 24766-77	3.3	106
87	Feature-based analysis of mouse prostatic intraepithelial neoplasia in histological tissue sections. *Journal of Pathology Informatics*, **2016**, 7, 5	4.4	7
86	Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer. *PLoS ONE*, **2016**, 11, e0150241	3.1	20
85	Copy number increase of oncoprotein CIP2A is associated with poor patient survival in human head and neck squamous cell carcinoma. *Journal of Oral Pathology and Medicine*, **2016**, 45, 329-37	3.3	5
84	Amplification of the 9p13.3 chromosomal region in prostate cancer. *Genes Chromosomes and Cancer*, **2016**, 55, 617-25	5	7
83	The Molecular Evolution of Castration-resistant Prostate Cancer. *European Urology Focus*, **2016**, 2, 506-513	3.1	23
82	Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. *Journal of Physical Education and Sports Management*, **2016**, 2, a000752	2.8	18
81	Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms. *Prostate*, **2016**, 76, 22-31	4.2	25
80	Construction of therapeutically relevant human prostate epithelial fate map by utilising miRNA and mRNA microarray expression data. *British Journal of Cancer*, **2015**, 113, 611-5	8.7	8
79	MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2. *Prostate* , **2015**, 75, 798-805	4.2	43
78	miR-25 Modulates Invasiveness and Dissemination of Human Prostate Cancer Cells via Regulation of □- and □-Integrin Expression. *Cancer Research*, **2015**, 75, 2326-36	10.1	83
77	The evolutionary history of lethal metastatic prostate cancer. *Nature*, **2015**, 520, 353-357	50.4	857
76	Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer. *Cancer Research*, **2015**, 75, 4026-31	10.1	56
75	MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets. *European Urology*, **2015**, 67, 7-10	10.2	55
74	Epigenetically altered miR-193b targets cyclin D1 in prostate cancer. *Cancer Medicine*, **2015**, 4, 1417-25	4.8	31
73	Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer. *Oncotarget*, **2015**, 6, 6235-50	3.3	22

72	Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer. *Oncotarget*, **2015**, 6, 12587-602	3.3	42
71	CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations. *Oncotarget*, **2015**, 6, 19661-70	3.3	21
70	C/D-box snoRNA-derived RNA production is associated with malignant transformation and metastatic progression in prostate cancer. *Oncotarget*, **2015**, 6, 17430-44	3.3	57
69	Long noncoding RNA in prostate, bladder, and kidney cancer. *European Urology*, **2014**, 65, 1140-51	10.2	471
68	A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding. *Nature Genetics*, **2014**, 46, 126-35	36.3	142
67	Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. *Science*, **2014**, 345, 1251343	33.3	250
66	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. *Nature Genetics*, **2014**, 46, 1103-9	36.3	331
65	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. *ELife*, **2014**, 3,	8.9	229
64	DOT1L-HES6 fusion drives androgen independent growth in prostate cancer. *EMBO Molecular Medicine*, **2014**, 6, 1121-3	12	13
63	Author response: Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer **2014**,		3
62	Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate. *Prostate*, **2013**, 73, 101-12	4.2	11
61	The mutational landscape of prostate cancer. *European Urology*, **2013**, 64, 567-76	10.2	144
60	Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 2333-44	4	104
59	Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. *Cancer Research*, **2013**, 73, 6757-69	10.1	35
58	DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. *Journal of Clinical Oncology*, **2013**, 31, 3250-8	2.2	102
57	Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. *Journal of Clinical Investigation*, **2013**, 123, 493-508	15.9	33
56	The Effect of AR Overexpression on Androgen Signaling in Prostate Cancer **2013**, 187-200		0
55	Androgen receptor (AR) aberrations in castration-resistant prostate cancer. *Molecular and Cellular Endocrinology*, **2012**, 360, 38-43	4.4	131

54	Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. *Oncogene*, **2012**, 31, 978-91	9.2	212
53	Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. *Oncogene*, **2012**, 31, 2153-63	9.2	100
52	Androgen receptor overexpression alters binding dynamics of the receptor to chromatin and chromatin structure. *Prostate*, **2012**, 72, 1223-32	4.2	19
51	Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. *Oncogene*, **2012**, 31, 4460-71	9.2	171
50	ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. *PLoS ONE*, **2011**, 6, e17979	3.7	49
49	Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells. *PLoS ONE*, **2011**, 6, e26595	3.7	7
48	MicroRNA in prostate, bladder, and kidney cancer: a systematic review. *European Urology*, **2011**, 59, 671-81	10.2	355
47	Confirmation of the association of TMPRSS2(exon 0):ERG expression and a favorable prognosis of primary prostate cancer. *European Urology*, **2011**, 60, 183-4	10.2	18
46	Androgen regulation of micro-RNAs in prostate cancer. *Prostate*, **2011**, 71, 604-14	4.2	129
45	The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers. *Genes Chromosomes and Cancer*, **2011**, 50, 499-509	5	39
44	Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. *Clinical Cancer Research*, **2010**, 16, 2845-51	12.9	97
43	miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. *International Journal of Cancer*, **2010**, 127, 1363-72	7.5	113
42	Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. *Cancer Research*, **2009**, 69, 8141-9	10.1	171
41	TCEB1 promotes invasion of prostate cancer cells. *International Journal of Cancer*, **2009**, 124, 95-102	7.5	23
40	Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. *Nature Medicine*, **2009**, 15, 559-65	50.5	513
39	Androgen regulation of the androgen receptor coregulators. *BMC Cancer*, **2008**, 8, 219	4.8	51
38	TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. *Clinical Cancer Research*, **2008**, 14, 3395-400	12.9	206
37	MicroRNA expression profiling in prostate cancer. *Cancer Research*, **2007**, 67, 6130-5	10.1	757

36	The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. *Genes Chromosomes and Cancer*, **2006**, 45, 639-45	5	115
35	Genetic aberrations in prostate cancer by microarray analysis. *International Journal of Cancer*, **2006**, 119, 1322-9	7.5	73
34	Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors. *BJU International*, **2006**, 97, 404-9	5.6	14
33	Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene. *Cancer Chemotherapy and Pharmacology*, **2005**, 55, 343-346	3.5	22
32	The molecular genetics of prostate cancer. *Urology*, **2003**, 62, 3-10	1.6	509
31	Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. *Genes Chromosomes and Cancer*, **2002**, 35, 66-73	5	39
30	Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library array. *Journal of Pathology*, **2001**, 193, 73-9	9.4	35
29	5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines. *Genes Chromosomes and Cancer*, **2001**, 30, 187-195	5	29
28	Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy. *Cancer Gene Therapy*, **2001**, 8, 137-44	5.4	33
27	Molecular genetics of prostate cancer. *Annals of Medicine*, **2001**, 33, 130-41	1.5	75
26	Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. *Cancer Research*, **2001**, 61, 3550-5	10.1	500
25	Mapping the amplification of EIF3S3 in breast and prostate cancer **2000**, 28, 203-210		36
24	Molecular cytogenetics of prostate cancer. *Microscopy Research and Technique*, **2000**, 51, 456-63	2.8	44
23	The androgen receptor as a therapeutic target in prostate cancer. *Expert Opinion on Therapeutic Targets*, **2000**, 4, 65-71		1
22	Androgen receptor gene mutations in hormone-refractory prostate cancer. *Journal of Pathology*, **1999**, 189, 559-63	9.4	76
21	Androgen receptor gene mutations in hormone-refractory prostate cancer **1999**, 189, 559		4
20	Molecular genetics of prostate cancer. *Annales Chirurgiae Et Gynaecologiae*, **1999**, 88, 11-6		10
19	Evidence for a prostate cancer susceptibility locus on the X chromosome. *Nature Genetics*, **1998**, 20, 175-9	36.3	592

18	Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. *Journal of Pathology*, **1997**, 183, 51-6	9.4	37
17	Optimizing DOP-PCR for universal amplification of small DNA samples in comparative genomic hybridization **1997**, 18, 94-101		93
16	Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1996**, 56, 57-63	2	40
15	In vivo amplification of the androgen receptor gene and progression of human prostate cancer. *Nature Genetics*, **1995**, 9, 401-6	36.3	1166
14	Reproducibility in DNA flow cytometric analysis of breast cancer: comparison of 12 laboratoriesV results for 67 sample homogenates. *Cytometry*, **1995**, 22, 115-27		42
13	Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. *Cancer Research*, **1995**, 55, 342-7	10.1	343
12	Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. *Journal of Pathology*, **1994**, 174, 275-82	9.4	148
11	Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. *Cytometry*, **1994**, 16, 93-9		105
10	Automated peak detection and cell cycle analysis of flow cytometric DNA histograms. *Cytometry*, **1994**, 16, 250-5		29
9	Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. *American Journal of Pathology*, **1994**, 145, 624-30	5.8	60
8	New prognostic factors in prostatic carcinoma. *European Urology*, **1993**, 24, 438-49	10.2	23
7	Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. *Journal of the National Cancer Institute*, **1992**, 84, 883-7	9.7	274
6	Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma. *Journal of Pathology*, **1992**, 168, 7-13	9.4	76
5	Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. *Modern Pathology*, **1992**, 5, 643-8	9.8	56
4	Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy. *British Journal of Cancer*, **1991**, 64, 578-82	8.7	46
3	Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. *Cytometry*, **1991**, 12, 413-21		66
2	Chromatin accessibility analysis uncovers regulatory element landscape in prostate cancer progression		4
1	Single-cell ATAC and RNA sequencing reveal pre-existing and persistent subpopulations of cells associated with relapse of prostate cancer		1